[1]熊亚岚,袁耿彪,郑晨曦,等.全身奥曲肽显像在儿童神经母细胞瘤诊断及分期中的应用价值[J].第三军医大学学报,2019,41(13):1275-1280.
 XIONG Yalan,YUAN Gengbiao,ZHENG Chengxi,et al.Application value of 99mTc-HTOC in diagnosis and staging of neuroblastoma in children[J].J Third Mil Med Univ,2019,41(13):1275-1280.
点击复制

全身奥曲肽显像在儿童神经母细胞瘤诊断及分期中的应用价值(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第13期
页码:
1275-1280
栏目:
临床医学
出版日期:
2019-07-15

文章信息/Info

Title:
Application value of 99mTc-HTOC in diagnosis and staging of neuroblastoma in children
作者:
熊亚岚袁耿彪郑晨曦饶茂华
重庆医科大学附属第二医院核医学科
Author(s):
XIONG Yalan YUAN Gengbiao ZHENG Chengxi RAO

MaohuaDepartment of Nuclear Medicine, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China

关键词:
奥曲肽神经母细胞瘤诊断分期儿童
Keywords:
octreotide neuroblastoma diagnosis staging children
分类号:
R739.4; R814.42; R981
文献标志码:
A
摘要:

目的探讨全身奥曲肽显像在儿童神经母细胞瘤(neuroblastoma,NB)诊断及分期中的应用价值。方法对本院2016年3月至2018年3月接诊的32例临床疑似NB并至少接受了一项传统影像学检查[超声、计算机断层扫描(computed tomography,CT)及核磁共振成像(magnetic resonance imaging, MRI)]的患儿进行全身99mTc-奥曲肽显像(99mTechnetium-Hydrazinonicotinyl-Tyr 3-Octreotide,99mTc-HTOC)检查,结果由两位主治或主任医师进行判定,参照标准为组织病理学、传统影像学及临床随访结果相结合。 结果99mTc-HTOC显像诊断灵敏度96.7%(29/30例),特异度50%(1/2例),阳性预测值96.7%(29/30例),阴性预测值50%(1/2例),诊断符合率达93.8%(30/32例)。有3例(10%)患儿行99mTc-HTOC显像后改变了初始分期,其中1例患儿从ⅡA期上升到Ⅳ期,其余2例患儿从Ⅲ期上升到Ⅳ期。 结论99mTc-HTOC显像提高了NB初始分期的准确性,可应用于儿童NB的诊断及分期。

Abstract:

ObjectiveTo investigate the application value of 99mtechnetium-hydrazinonicotinyl-tyr 3-octreotide (99mTc-HTOC) imaging in the diagnosis and staging of neuroblastoma (NB) in children.  Methods99mTc-HTOC scintigraphy was performed on 32 NB suspected children who received at least 1 conventional imaging examination [ultrasound examination, computed tomography (CT), or magnetic resonance imaging (MRI)] from March 2016 to March 2018 in our hospital. Images were evaluated by 2 experienced nuclear medicine physicians or archiaters. The combination of the results of pathological examination, traditional imaging examination and clinical follow-up were reference standards.  Results The sensitivity of 99mTc-HTOC imaging was 96.7% (29/30), specificity was 50% (1/2), positive predictive value was 96.7% (29/30), negative predictive value was 50% (1/2) and diagnostic coincidence rate was 93.8% (30/32). The initial stage was changed in 3 patients (10%) after the 99mTc-HTOC imaging. One of the patients was increased from stage ⅡA to stage Ⅳ, and the remaining 2 patients were increased from stage Ⅲ to stage Ⅳ.  Conclusion99mTc-HTOC imaging improves the accuracy of NB initial staging, and can be used in the diagnosis and staging of NB in children.

参考文献/References:

[1]MATSUSHITA K, UCHIDA K, SAIGUSA S, et al. Low NDRG1 mRNA expression predicts a poor prognosis in neuroblastoma patients[J]. Prediatr Surg Int,2013,29(4):363-368.DOI: 10.1007/s00383-012-3248-6.
[2]SWIFT C C, EKLUND M J, KRAVEKA J M, et al. Updates in diagnosis, management, and treatment of neuroblastoma[J]. Radiographics, 2018, 38(2): 566-580. DOI:10.1148/rg.2018170132.
[3]WHITTLE S B, SMITH V, DOHERTY E, et al. Overview and recent advances in the treatment of neuroblastoma[J]. Expert Rev Anticancer Ther, 2017,17(4):369-386.DOI:10.1080/14737140.2017.1285230.
[4]卢晓莉, 张俊, 王峰, 等. 68Ga-DOTA-NOC胰腺癌生长抑素受体靶向显像的实验研究[J]. 中华核医学与分子影像杂志, 2013,33(5):372-376. DOI:10.3760/cma.j.issn.2095-2848.2013.05.014.
LU X L, ZHANG J, WANG F, et al. 68Ga-DOTA-NOC somatostatin receptor-targeting imaging in pancreatic carcinoma[J]. Chin J Nucl Med Mol Imaging, 2013,33(5):372-376. DOI:10.3760/cma.j.issn. 2095-2848.2013.05.014.
[5]TAEB D, GARRIGUE P, BARDIS M, et al. Application and dosimetric requirements for gallium-68-labeled somatostatin analogues in targeted radionuclide therapy for gastroenteropancreatic neuroendocrine tumors[J]. PET Clin, 2015, 10(4): 477-486. DOI:10.1016/j.cpet.2015.06.001.
[6]NARAYANAN S, KUNZ P L. Role of somatostatin analogues in the treatment of neuroendocrine tumors[J]. Hematol Oncol Clin North Am, 2016, 30(1): 163-177. DOI: 10.1016/j.hoc.2015.09.008.
[7]PROVOST C, PRIGNON A, CAZES A, et al. 68Ga-DOTATOC and FDG PET imaging of preclinical neuroblastoma models[J]. Anticancer Res, 2016, 36(9): 4459-4466. DOI:10.21873/anticanres.10990.
[8]MIKOLAJCZAK R, MAECKE H R. Radiopharmaceuticals for somatostatin receptor imaging[J]. Nucl Med Rev Cent East Eur, 2016,19(2):126-132. DOI:10.5603/NMR.2016.0024.
[9]KONG G, HOFMAN M S, MURRAY W K, et al. Initial experience with gallium-68 DOTA-octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma[J]. J Pediatr Hematol Oncol, 2016, 38(2): 87-96. DOI:10.1097/MPH.0000000000000411.
[10]SIMON T, HERO B, SCHULTE J H, et al. 2017 GPOH guidelines for diagnosis and treatment of patients with neuroblastic tumors[J]. Klin Padiatr, 2017, 229(3): 147-167. DOI:10.1055/s-0043-103086.
[11]DHULL V S, SHARMA P, PATEL C, et al. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma:comparison with 131I-MIBG scintigraphy[J]. Nucl Med Commun, 2015,36(10): 1007-1013. DOI: 10.1097/MNM.0000000 000000347.
[12]王剑杰, 周鑫, 王骁, 等. 18F-FDG PET/CT儿童神经母细胞瘤诊断分期中的应用[J]. 中国医学影像学杂志, 2014,22(12):936-940,942. DOI: 10.3969/j.issn. 1005-5185.2014.12.016.
WANG J J, ZHOU X, WANG X, et al. 18F-FDG PET/CT in the staging of pediatric neuroblastoma[J]. Chin J Med Imaging, 2014,22(12):936-940,942. DOI : 10.3969/j.issn.1005-5185.2014.12.016.
[13]OLSEN I H, LANGER S W, FEDERSPIEL B H, et al. 68Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas:strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2[J]. Am J Nucl Med Mol Imaging, 2016, 6(1):59-72.
[14]PANDEY G K, KANDURI C. Long noncoding RNAs and neuroblastoma[J]. Oncotarget, 2015, 6(21): 18265-18275. DOI:10.18632/oncotarget.4251.
[15]ALEXANDER N, VALI R, AHMADZADEHFAR H, et al. Review: the role of radiolabeled dota-conjugated peptides for imaging and treatment of childhood neuroblastoma[J]. Curr Radiopharm, 2018,11(1):14-21. DOI:10.2174/1874471011666171215093112.

相似文献/References:

[1]王彬,张鑫.28例儿童晚期神经母细胞瘤化疗的护理[J].第三军医大学学报,2007,29(20):1942.
[2]娄茜,陈维贤,史静,等.CSF-DKK1作为标志物在神经母细胞瘤诊断与治疗监测中的临床价值[J].第三军医大学学报,2013,35(15):1587.
 Lou Qian,Chen Weixian,Shi Jing,et al.Clinical significance of CSF-DKK1 as a biomarker for diagnosis and therapeutic monitoring of neuroblastoma[J].J Third Mil Med Univ,2013,35(13):1587.
[3]张红宾,张翼军,夏顺中,等.以关节疼痛和广泛骨质破坏为表现的神经母细胞瘤1例[J].第三军医大学学报,2003,25(10):0.[doi:10.16016/j.1000-5404.2003.10.015 ]
[4]朱梅刚,张桂香,朱思和,等.电镜观察在淋巴网状组织良恶性病变诊断价值的探讨[J].第三军医大学学报,1987,09(03):0.[doi:10.16016/j.1000-5404.1987.03.021 ]

更新日期/Last Update: 2019-07-08